Intravascular volume replacement therapy with synthetic colloids: Is there an influence on renal function?

Anesthesia and Analgesia

Volumn 96, Issue 2, 2003, Pages 376-382

  Boldt, Joachim ^a   Priebe, Hans Joachim ^b  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; DEXTRAN; GELATIN; HETASTARCH;

ARTICLE; BLOOD VOLUME; CLINICAL TRIAL; COLLOID; DRUG SAFETY; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; MEDICAL LITERATURE; PRIORITY JOURNAL; RISK FACTOR; SUBSTITUTION THERAPY;

CLINICAL TRIALS; COLLOIDS; FLUID THERAPY; HUMANS; KIDNEY; KIDNEY FAILURE; KIDNEY FUNCTION TESTS;

EID: 0037302026     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-200302000-00014     Document Type: Article

References (51)

1. Mythen MG, Salmon JB, Webb AR. The rational administration of colloids. Blood Rev 1993;7:223-8.
2. Vermeulen LC, Ratko MA, Estad BL, et al. A paradigm for consensus: the university hospital consortium guidelines for the use of albumin, nonprotein colloids, and crystalloid solutions. Arch Intern Med 1995;155:373-9.
3. Schierhout G, Roberts I. Fluid resuscitation with colloids or crystalloids in critically ill patients: a systematic review of randomised trials. BMJ 1998;316:961-4.
4. Choi P, Yip G, Quinonez L, Cook D. Crystalloids versus colloids in fluid resuscitation: a systematic review. Crit Care Med 1999; 27:200-10.
5. Astiz ME, Rackow EC. Crystalloid-colloid controversy revisited. Crit Care Med 1999;27:34-5.
6. Boldt J, Lenz M, Kumle B, Papsdorf M. Volume replacement strategies on intensive care units: results from a postal survey. Intensive Care Med 1998;24:147-51.
7. Waldhausen P, Kiesewetter H, Leipnitz G, et al. Hydroxyethyl starch induced transient renal insufficiency in glomerular failure. Acta Med Austriaca 1991;18(Suppl 1):52-5.
8. Dehne MG, Mühling J, Sablotzki A, Hempelmann G. Influence of hydroxethylstarch on renal function in intensive care patients. Anasthesiol Intensivmed Notfallmed Schmerzther 1997; 32:348-54.
9. Legendre C, Thervet E, Page B, et al. Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney transplantation. Lancet 1993;342:248-9.
10. Druml W, Pölzleitner D, Laggner AN, et al. Dextran-40, acute renal failure, and elevated plasma oncotic pressure. N Engl J Med 1988;318:252-3.
11. Cittanova ML, Leblanc I, Legendre C, et al. Effect of hydroxy-ethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 1996;348:1620-2.
12. Schortgen F, Lacherade JC, Bruneel F, et al. Effects of hydroxy-ethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 2001;357:911-6.
13. Prough DS, Johnston WE. Fluid restoration in septic shock: no solution yet. Anesth Analg 1989;69:699-704.
14. Warren BB, Durieux ME. Hydroxyethylstarch: safe or not? Anesth Analg 1997;84:206-12.
15. Whinney RR, Cohn SM, Zacur SJ. Fluid resuscitation for trauma patients in the 21st century. Curr Opin Crit Care 2000;6:395-400.
16. Peron S, Mouthon L, Guettier C, et al. Hydroxyethyl starch-induced renal insufficiency after plasma exchange in a patient with polymyositis and liver cirrhosis. Clin Nephrol 2001;55: 408-11.
17. De Labarthe A, Jacobs F, Blot F, Glotz D. Acute renal failure secondary to hydroxyethylstarch administration in a surgical patient. Am J Med 2001;111:417-8.
18. Byrick RJ, Rose DK. Review article: pathophysiology and prevention of acute renal failure - the role of the anaesthetist. Can J Anaesth 1990;37:457-67.
19. Rahn KH. Acute disturbances of renal function. Chest 1991; 100(Suppl):197S-9.
20. Kulka PJ, Tryba M, Zenz M. Preoperative alpha-2-adrenergic receptor agonists prevent the deterioration of renal function after cardiac surgery: results of a randomized, controlled trial. Crit Care Med 1996;24:947-52.
21. Lote CJ, Harper L, Savage COS. Mechanisms of acute renal failure. Br J Anaesth 1996;77:82-9.
22. Ducke G, Briedis JH, Weaver RA. Renal support in critically ill patients: low dose dopamine or low dose dobutamine? Crit Care Med 1994;22:1919-25.
23. Aronson S, Blumenthal R. Perioperative renal dysfunction and cardiovascular anesthesia: concerns and controversies. J Cardiothorac Vasc Anesth 1998;12:567-86.
24. Chew STH, Newman MF, White WD, et al. Preliminary report on the association of apolipoprotein E polymorphisms, with postoperative peak serum creatinine concentrations in cardiac surgical patients. Anesthesiology 2000;93:325-31.
25. Lindeman RD. Changes in renal function with aging: implications for treatment. Drugs Aging 1992;2:423-31.
26. Ritschel WA. Gerontokinetics: the pharmacokinetics of drugs in the elderly patient. Caldwell, NJ: Telford Press, 1988;114-24.
27. Moran M, Kapsner C. Acute renal failure associated with elevated plasma oncotic pressure. N Engl J Med 1987;317:150-3.
28. Beyer R, Harmening U, Rittmeyer O, et al. Use of modified fluid gelatin and hydroxyethyl starch for colloidal volume replacement in major orthopaedic surgery. Br J Anaesth 1997;78:44-50.
29. Hussain SF, Drew PJT. Acute renal failure after infusion of gelatins. BMJ 1989;299:1137-8.
30. Kurnik BRC, Singer F, Groh WC. Case report: dextran-induced acute renal failure. Am J Med Sci 1991;302:28-30.
31. Daniel WJ, Mohamed SD, Metheson NA. Treatment of mesenteric embolism with dextran 40. Lancet 1966;1:567-9.
32. Kief H, Englelhart K. Reabsorptive Vacuolisation der gewundenen Nierenhauptstuecke (sog. osmotische Nephrose). Frankf Z Pathol 1966;75:53-9.
33. Figueroa JE, Burgos-Calderon R. Renal toxicity of low molecular weight dextran: a review of the literature. J La State Med Soc 1974;126:425-7.
34. Feest TG. Low molecular weight dextran: a continuing cause of acute renal failure. BMJ 1976;2:1300-1.
35. Traylor RJ, Pearl R. Crystalloid versus colloid: all colloids are not created equal. Anesth Analg 1996;83:209-12.
36. Iana A, Schwartz D. Renal tubular cellular and molecular events in acute renal failure. Nephron 1994;68:413-8.
37. Chinitz JL, Kim KE, Onesti G, Swartz C. Pathophysiology and prevention of dextran-40-induced anuria. J Lab Clin Med 1971; 77:76-87.
38. Rozich JD, Paul RV. Acute renal failure precipitated by elevated colloid osmotic pressure. Am J Med 1989;87:358-60.
39. London MJ, Ho SJ, Triedman JK, et al. A randomized clinical trial of 10% pentastarch (low molecular weight hydroxyethyl starch) versus 5% albumin for plasma volume expansion after cardiac operations. J Thorac Cardiovasc Surg 1989;97:785-97.
40. Stockwell MA, Scott A, Day A, Soni N. Colloid solutions in the critically ill: a randomised comparison of albumin and polygeline 2 serum albumin concentration and incidences of pulmonary oedema and acute renal failure. Anaesthesia 1992;47:7-9.
41. Gines A, Fernandez-Esparrach G, Monescillo A. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996;111:1002-10.
42. Vogt NH, Bothner U, Lerch G, et al. Large-dose administration of 6% hydroxyethyl starch 200/0.5 for total hip arthroplasty: plasma homeostasis, hemostasis, and renal function compared to use of 5% human albumin. Anesth Analg 1996;83:262-8.
43. Boldt J, Müller M, Mentges D, et al. Volume therapy in the critically ill: is there a difference? Intensive Care Med 1998;24: 28-36.
44. Kumle B, Boldt J, Piper SN, et al. The influence of different intravascular volume replacement regimens on renal function in the elderly. Anesth Analg 1999;89:1124-30.
45. Allison KP, Gosling P, Jones S, et al. Randomized trial of hydroxyethyl starch versus gelatine for trauma resuscitation. J Trauma 1999;47:1114-21.
46. Deman A, Peeters P, Sennesael J. Hydroxyethyl starch does not impair immediate renal function in kidney transplant recipients: a retrospective, multicenter analysis. Nephrol Dial Transplant 1999;14:1517-20.
47. Boldt J, Lehmann A, Römpert R, et al. Volume therapy with a new hydroxyethyl starch solution in cardiac surgical patients before cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2000;14:264-8.
48. Dehne MG, Mühling J, Sablotzki A, et al. Hydroxyethylstarch (HES) does not directly affect renal function in patients with no prior renal impairment. J Clin Anesth 2001;13:103-11.
49. Cittanova ML, Zubicki A, Savu C, et al. The chronic inhibition of angiotensin-converting enzyme impairs postoperative renal function. Anesth Analg 2001;93:1111-5.
50. Eger EI II, Gong D, Koblin DD, et al. Dose-related biochemical markers of renal injury after sevoflurane versus desflurane anesthesia in volunteers. Anesth Analg 1997;85:1154-63.
51. Jungheinrich C, Scharf R, Wargenau M, et al. The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethylstarch 130/0.4 (6%, 500 mL) in mild-to-severe renal impairment. Anesth Analg 2002;95:544-51.